Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer.

Trial Profile

Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
    • 31 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top